Priority setting for orphan drugs: An international comparison
-
Novo Nordisk rejects Baxter patent claim over Novoeight
Pharma Live, , Intellectual Property Rights, 0
COPENHAGEN, May 20 (Reuters) – Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that...
-
Louisiana Challenge’s AstraZeneca on Antitrust Claims for Asserting Invalid Drug Patents – Courtesy(PATENTLYO)
Pharma Live, , Intellectual Property Rights, 0
In March 2015, the state of Louisiana filed suit against AstraZeneca alleging antitrust violations based upon the company’s actions of...
-
Here’s a lucrative idea: Turn a drug into an orphan med, reap 6 months extra exclusivity – Courtesy (Fierce Pharma)
Pharma Live, , Intellectual Property Rights, 0
Would-be makers of rare disease meds, rejoice: A 6-month exclusivity extension, proposed last year in Congress, has returned. The 21st...
-
Amarantus Bioscience Receives Notice Of Allowance For U.S. Patent Application Covering Proprietary Compositions Of Matter And Methods Of Use for manufacture -Courtesy (Biospace)
Pharma Live, , Intellectual Property Rights, 0
SAN FRANCISCO and GENEVA, May 5, 2015 (GLOBE NEWSWIRE) — Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on...
-
Maximizing Use of the USPTO’s Patent Application Alert Service
Pharma Live, , Intellectual Property Rights, 0
The U.S. Patent and Trademark Office (USPTO) recently launched the Patent Application Alert Service (PAAS), a free electronic tool aimed to...
-
First Look At False Marking Under The AIA – Courtesy (Pharma Patents)
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 14 MAY 2015POSTED IN FEDERAL CIRCUIT DECISIONSIn Sukumar v. Nautilus, Inc., the Federal Circuit took its first...
-
Activists Urge Lawmakers to Prioritize Patients Over Patents – Courtesy(Jakarta Globe)
Pharma Live, , Intellectual Property Rights, 0
Jakarta. Public health activists have called on the government to review a number of key points included in a revised...
-
Evaluating and improving orphan drug regulations in Europe: A Delphi policy study
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0168851012002461-mainDownload